A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels-Reference-Cited by-同舟云学术

A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels

Published:2001-09-15 Issue:6 Volume:98 Page:1992-1993
ISSN:1528-0020
Container-title:Blood
language:en
Short-container-title:

Author:

Brouwers Geert-Jan¹,Vos Hans L.¹,Leebeek Frank W. G.¹,Bulk Saskia¹,Schneider Mark¹,Boffa Michael¹,Koschinsky Marlys¹,van Tilburg Nico H.¹,Nesheim Michael E.¹,Bertina Rogier M.¹,Gómez Garcı́a Encarnación B.¹

Affiliation:

1. Correspondence: Geert-Jan Brouwers, Department of Hematology, Erasmus University Medical Center Rotterdam, Dr Molewaterplein 50, 3015 GE, Rotterdam, The Netherlands

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/98/6/1992/1676915/h8180101985f.pdf

Reference7 articles.

1. Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled.;Henry;Blood.,2001

2. Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms.;Zhao;Thromb Haemost.,1998

3. Identification of polymorphisms in the TAFI gene promoter; relationship with plasma TAFI levels and risk of venous thrombosis [abstract].;Franco;Blood.,2000

4. A polymorphism at position -438 in the promoter region of thrombin-activatable fibrinolysis inhibitor (TAFI) is strongly associated with plasma antigen levels in healthy older men and women [abstract].;Crainich;Circulation.,2000

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Thrombin activatable fibrinolysis inhibitor plasma levels and TAFI Thr325Ile genetic polymorphism in a cohort of Egyptian sickle cell disease patients and impact on disease severity;Pediatric Blood & Cancer;2024-03-23

2. Fibrinolysis biomarker, thrombin, and activated protein C level alterations after coagulation activation depend on type of thrombophilia and clinical phenotype;Research and Practice in Thrombosis and Haemostasis;2024-02

3. Coagulation activation-induced fibrinolysis biomarker changes depend on thrombophilic risk factors and their clinical phenotype: an interventionalin vivostudy;2023-11-26

4. Brain Expression of CPB2 and Effects of Cpb2 Deficiency in Mouse Models of Behavior;Thrombosis and Haemostasis;2023-08-02

5. Profibrinolytic effects of rivaroxaban are mediated by thrombin-activatable fibrinolysis inhibitor and are attenuated by a naturally occurring stabilizing mutation in enzyme;Journal of Thrombosis and Thrombolysis;2023-06-13